Amgen
AMGN
$451.83
+0.87%
Amgen is a global biotechnology leader that discovers, develops, manufactures, and markets human therapeutics, with a portfolio spanning hematology/oncology support (Epogen, Aranesp, Neupogen, Neulasta), inflammatory disease (Enbrel, Otezla), bone health (Prolia, Xgeva, Evenity), oncology (Kyprolis, Blincyto, Vectibix, Imdelltra), rare disease via the 2023 Horizon acquisition (Tepezza, Krystexxa, Uplizna), and a growing biosimilars franchise. It is one of the largest pure-play biotechs by revenue and market capitalization, distinguished by its scale manufacturing, entrenched nephrology/oncology relationships, and a dividend-paying profile unusual among biotech peers. The current investor narrative centers on whether Amgen can offset mature-franchise erosion (Enbrel, Otezla, Prolia biosimilar/IRA pressure) with newer growth drivers, most notably MariTide, its once-monthly obesity candidate that could carve a convenience niche against Eli Lilly and Novo Nordisk, alongside pipeline momentum in Imdelltra and Tezspire. Sentiment has been further shaped by the Horizon integration, drug-tariff exemption positioning, and periodic regulatory noise such as the Tavneos safety scrutiny flagged by its Japanese partner, all set against a stock that has delivered strong relative performance over the past year.…
AMGN
Amgen
$451.83
Related headlines
Investment Opinion: Should I buy AMGN Today?
We rate AMGN a Hold. The core thesis is that while the company has attractive growth optionality from MariTide and a solid dividend, the risk/reward is balanced given the stock's 50% rally over the past year and the analyst consensus target of $396.70, which implies 9.7% downside. The high leverage and mature franchise erosion further temper enthusiasm. Supporting evidence includes a forward PE of 17.9x, which is reasonable but not deeply discounted; revenue growth of 9.68% YoY in Q2 2026; gross margin expansion to 72.04%; and TTM free cash flow of $10.2 billion. The dividend yield of 2.91% is attractive for income investors. However, the PEG ratio of 0.26 suggests undervaluation relative to growth, creating a mixed picture. Key risks that could invalidate the Hold rating include a failure of MariTide in clinical trials, accelerated erosion of Enbrel/Otezla, or a ratings downgrade due to leverage. We would upgrade to Buy if the stock pulls back to the analyst average target of ~$397 or if MariTide shows compelling Phase 3 data. We would downgrade to Sell if revenue growth decelerates below 5% or if the debt burden becomes unmanageable. Overall, the stock appears fairly valued to slightly overvalued relative to its own history and peers, given the recent run-up.
Sign up to view all
AMGN 12-Month Price Forecast
Amgen presents a balanced risk/reward profile. The company's strong cash flow, growing dividend, and pipeline optionality are offset by high leverage, mature franchise erosion, and a stock that has already rallied significantly. The analyst consensus hold and target price below the current level suggest limited near-term upside. We would upgrade to bullish if MariTide Phase 3 data exceeds expectations or if the stock pulls back to the $380-400 range. Conversely, a downgrade to bearish would follow any pipeline setback or acceleration in core franchise declines.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Amgen's 12-month outlook, with a consensus price target around $397.32 and implied upside of -12.1% versus the current price.
Average Target
$397.32
0 analysts
Implied Upside
-12.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$225 - $500
Analyst target range
Bulls vs Bears: AMGN Investment Factors
The bull case rests on Amgen's accelerating revenue growth (9.68% YoY), expanding gross margins (72.04%), and the optionality from MariTide, all available at a modest 17.9x forward PE with a 2.91% dividend yield. However, the bear case is equally compelling: extreme leverage (D/E of 6.31), a consensus hold rating with a price target below the current price, and persistent erosion of mature franchises. The strongest evidence currently favors the bear side on valuation and analyst sentiment, but the bull side has momentum and cash flow. The single most important tension is whether MariTide can become a meaningful growth driver before the core franchises erode further—this binary outcome will likely determine the stock's direction over the next 12 months.
Bullish
- MariTide obesity optionality: MariTide's once-monthly dosing could carve a convenience niche in the obesity market, a potential multi-billion-dollar opportunity that is not reflected in the current 17.9x forward PE. Recent news highlights this catalyst, and success would diversify Amgen beyond its mature franchises.
- Strong relative performance: AMGN has outperformed the S&P 500 by 36.8 percentage points over the past year (49.97% vs. 13.13%) and by 22.6 points YTD. This momentum reflects investor confidence in the pipeline and earnings resilience.
- Revenue growth accelerating: Q2 2026 revenue grew 9.68% YoY to $10.05 billion, with gross margin expanding to 72.04% from 67.15% a year earlier. The top-line acceleration and margin improvement suggest operating leverage.
- Attractive valuation vs. growth: Forward PE of 17.9x and PEG of 0.26 indicate the stock is cheap relative to expected earnings growth. The dividend yield of 2.91% adds income appeal, and the payout ratio of 66.5% is sustainable given strong cash flow.
Bearish
- Extreme leverage constrains flexibility: Debt-to-equity of 6.31 is exceptionally high, a legacy of the Horizon acquisition. Interest expense of $673 million in Q2 2026 consumes a significant portion of operating income, limiting strategic options.
- Analyst consensus hold with downside: The average analyst target of $396.70 implies a 9.7% downside from the current price of $439.26, and the consensus recommendation is 'hold' (mean 2.65). The low target of $225 suggests deep skepticism about pipeline execution.
- Mature franchise erosion: Key drugs like Enbrel, Otezla, and Prolia face biosimilar and IRA pricing pressure. Q4 2025 net income fell to $1.33 billion (13.5% margin) from $627 million a year earlier, highlighting earnings volatility from these headwinds.
- Tavneos safety and regulatory risk: Amgen's Japanese partner urged caution on Tavneos due to data manipulation and safety concerns, creating reputational and financial risk. This regulatory noise could escalate and impact the rare disease franchise.
AMGN Technical Analysis
Beta
0.41
0.41x market volatility
Max Drawdown
-16.6%
Largest decline past year
52-Week Range
$288-$455
Price range past year
Annual Return
+54.7%
Cumulative gain past year
| Period | AMGN Return | S&P 500 |
|---|---|---|
| 1m | +8.1% | +0.9% |
| 3m | +16.6% | +4.1% |
| 6m | +37.0% | +7.2% |
| 1y | +54.7% | +12.4% |
| ytd | +37.9% | +13.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
AMGN Fundamental Analysis
Quarterly Revenue
$10.1B
2026-06
Revenue YoY Growth
+9.7%
YoY Comparison
Gross Margin
72.0%
Latest Quarter
Free Cash Flow
$10.2B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is AMGN Overvalued?
PE
22.8x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 11x~33x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.1x
Enterprise Value Multiple
Investment Risk Disclosure
Amgen's financial risk is dominated by its massive debt load, with a debt-to-equity ratio of 6.31 and interest expense of $673 million in Q2 2026 alone. While free cash flow of $10.2 billion TTM covers interest comfortably, the high leverage limits financial flexibility and increases sensitivity to rising rates. Additionally, the company's current ratio of 1.14 is barely above 1, indicating tight liquidity. Revenue concentration in mature drugs like Enbrel and Otezla, which face biosimilar and IRA pressure, adds to earnings volatility—Q4 2025 net margin was only 13.5% versus 33.7% in Q3 2025. Market and competitive risks include valuation compression if growth slows; the stock trades at 22.8x trailing earnings and 20.3x book, which is rich for a company with a 2.65 analyst rating (hold). The obesity market is fiercely competitive, with Eli Lilly and Novo Nordisk dominating, and Amgen's late entry via MariTide may struggle to gain share. Regulatory risks, such as the Tavneos safety scrutiny, could damage reputation and sales. The low beta of 0.407 offers some defense against market-wide selloffs, but sector rotation away from healthcare could still pressure the stock. In a worst-case scenario, if MariTide fails in trials or the competitive landscape proves too tough, and mature franchises erode faster than expected, the stock could retest its 52-week low of $288, representing a 34.4% decline from the current price of $439.26. The analyst low target of $225 implies an even steeper 48.8% downside, reflecting the potential for a severe de-rating if growth prospects diminish.
FAQ
The most severe risk is financial: debt-to-equity of 6.31 and interest expense of $673 million per quarter leave little room for error. Second, competitive risk in obesity is intense, with Eli Lilly and Novo Nordisk dominating and Amgen's MariTide yet to prove itself. Third, mature franchise erosion from biosimilars and IRA pricing could accelerate, as seen in Q4 2025's net margin of 13.5%. Fourth, regulatory risk from Tavneos safety concerns could escalate. These risks are ranked by severity, with financial leverage being the most immediate threat to the investment thesis.
Our 12-month forecast has three scenarios: bull case (25% probability) target $480-500, base case (50%) target $380-420, and bear case (25%) target $288-320. The base case is most likely, assuming revenue growth of 6-8% and MariTide capturing a modest share of the obesity market. The key assumption is that no major pipeline setbacks occur and that the company manages its debt load. The wide range reflects the binary nature of MariTide's success and the high leverage.
AMGN appears fairly valued to slightly overvalued. The trailing PE of 22.8x and forward PE of 17.9x are in line with large-cap biotech peers, but the price-to-book ratio of 20.3x is steep due to high leverage. The PEG ratio of 0.26 suggests undervaluation relative to expected earnings growth, but this is offset by the analyst target implying downside. Compared to its own history, the stock is trading near the high end of its range, with a 52-week high of $450.98. The market is pricing in successful execution of the pipeline, particularly MariTide, and any disappointment could lead to multiple compression.
AMGN is a good buy only for specific investor profiles. The stock has rallied 50% over the past year, and the analyst consensus target of $396.70 implies 9.7% downside, suggesting limited near-term upside. However, the forward PE of 17.9x and PEG of 0.26 indicate the stock is reasonably valued relative to growth, and the 2.91% dividend yield appeals to income seekers. The biggest downside risk is the high debt load (D/E of 6.31) and potential MariTide failure. Long-term investors with a tolerance for volatility may find the risk/reward acceptable, especially on pullbacks to the $380-400 range.
AMGN is more suitable for long-term investment (minimum 3-5 years) given its pipeline-dependent growth story and high leverage. The low beta of 0.407 and dividend yield of 2.91% make it a defensive holding, but near-term volatility could be high around clinical trial readouts and earnings. Short-term traders might exploit swings between $400 and $450, but the risk/reward favors patient investors who can wait for MariTide data and debt reduction. A suggested minimum holding period is 3 years to allow pipeline maturation and leverage improvement.